Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Daiichi Sankyo
Chinese Patent Office
Argus Health
Boehringer Ingelheim
Medtronic
US Department of Justice
Baxter
Express Scripts
McKinsey

Generated: August 21, 2017

DrugPatentWatch Database Preview

ILUVIEN Drug Profile

« Back to Dashboard

What is the patent landscape for Iluvien, and when can generic versions of Iluvien launch?

Iluvien is a drug marketed by Alimera Sciences Inc and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and sixty-five patent family members in twenty-six countries.

The generic ingredient in ILUVIEN is fluocinolone acetonide. There are twelve drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the fluocinolone acetonide profile page.

Summary for Tradename: ILUVIEN

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list42
Clinical Trials: see list6
Patent Applications: see list3,750
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ILUVIEN at DailyMed

Pharmacology for Tradename: ILUVIEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alimera Sciences Inc
ILUVIEN
fluocinolone acetonide
IMPLANT;INTRAVITREAL201923-001Sep 26, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Alimera Sciences Inc
ILUVIEN
fluocinolone acetonide
IMPLANT;INTRAVITREAL201923-001Sep 26, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Alimera Sciences Inc
ILUVIEN
fluocinolone acetonide
IMPLANT;INTRAVITREAL201923-001Sep 26, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Alimera Sciences Inc
ILUVIEN
fluocinolone acetonide
IMPLANT;INTRAVITREAL201923-001Sep 26, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Alimera Sciences Inc
ILUVIEN
fluocinolone acetonide
IMPLANT;INTRAVITREAL201923-001Sep 26, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ILUVIEN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,439,249Inhibitors of phosphatases► Subscribe
9,192,579Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof► Subscribe
8,574,659Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof► Subscribe
8,574,613Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof► Subscribe
8,815,284Bioerodible sustained release drug delivery systems► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ILUVIEN

Country Document Number Estimated Expiration
MexicoPA04011004► Subscribe
Argentina028372► Subscribe
South Korea100854541► Subscribe
Hong Kong1148931► Subscribe
World Intellectual Property Organization (WIPO)2005051234► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ILUVIEN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014000063Germany► SubscribePRODUCT NAME: FLUOCINOLONACETONID; NAT. REGISTRATION NO/DATE: 82809.00.00 20120720; FIRST REGISTRATION: GB PL 27813/0001 20120504
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
AstraZeneca
Teva
Deloitte
Cipla
Daiichi Sankyo
Novartis
Moodys
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot